Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data

被引:54
作者
Xu, Chuanhui [1 ]
Yi, Zixi [2 ]
Cai, Ruyi [2 ]
Chen, Ru [3 ]
Thong, Bernard Yu-Hor [1 ]
Mu, Rong [2 ]
机构
[1] Tan Tock Seng Hosp, Dept Rheumatol Allergy & Immunol, Singapore 308433, Singapore
[2] Peking Univ Third Hosp, Dept Rheumatol & Immunol, 49 Huayuan North Rd, Beijing 100191, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China
关键词
Rheumatic diseases; COVID-19; Outcomes; SARS-CoV-2; CORTICOSTEROIDS; ARTHRITIS; COHORT; SERIES;
D O I
10.1016/j.autrev.2021.102778
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: The impact of rheumatic diseases on COVID-19 infection remains poorly investigated. Here we performed a systematic review and meta-analysis to evaluate the outcomes of COVID-19 in patients with rheumatic diseases. Methods: We systematically searched PubMed, Embase, Cochrane Library, Scopus and preprint database up to 29th August 2020, for publications with confirmed COVID-19 infection in patients with rheumatic diseases. The primary outcomes were the rates of hospitalization, oxygen support, intensive care unit (ICU) admission and death. A meta-analysis of effect sizes using the random-effects models was performed, and meta-regression analyses were performed to explore heterogeneity. The data from the COVID-19 Global Rheumatology Alliance physician registry (the COVID-19 GRA) was used as a reference. Results: A total of 31 articles involving 1138 patients were included in this systematic review and meta-analysis. The publications were from Europe, Asia and North America, but none from other continents. The overall rates of hospitalization, oxygen support, ICU admission and fatality among COVID-19 infected patients with rheumatic diseases were 0.58 (95% confidence interval (CI) 0.48-0.67), 0.33 (95% CI 0.21-0.47), 0.09 (95% CI 0.05-0.15) and 0.07 (95% CI 0.03-0.11), respectively. The rate of oxygen support in Europe (0.48, 95% CI 0.4-0.57) was higher than that in other continents. Among all hospitalized patients, the rates of oxygen support, ICU admission and fatality were 0.61 (95% CI 0.48-0.73), 0.13 (95% CI 0.07-0.21) and 0.13 (95% CI 0.09-0.18), respectively. The fatality rate was highest in Europe (0.19, 95% CI 0.15-0.24). The fatality rate was higher both in this meta-analysis and the COVID-19 GRA (7.0% and 6.7%, respectively) than that (3.4%) in WHO database, although the age, gender and comorbidity were not matched. Conclusion: Patients with rheumatic diseases remain vulnerable with substantial rates of severe outcomes and a geographic variation. More studies were urgently needed to elucidate the risk factors of severe outcomes in this population.
引用
收藏
页数:8
相关论文
共 61 条
  • [1] Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis
    Akiyama, Shintaro
    Hamdeh, Shadi
    Micic, Dejan
    Sakuraba, Atsushi
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (03) : 384 - 391
  • [2] [Anonymous], CORONAVIRUS DIS COVI
  • [3] [Anonymous], Coronavirus (COVID-19) update: FDA issues emergency use authorization for potential COVID-19 treatment
  • [4] COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs
    Ansarin, Khalil
    Taghizadieh, Ali
    Safiri, Saeid
    Malek Mahdavi, Aida
    Ranjbar, Shirin
    Teymouri, Soheil
    Ahangari Maleki, Masoud
    Khabbazi, Alireza
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (10)
  • [5] No increased rate of SARS-CoV-2 infection for patients with inflammatory rheumatic diseases compared with the general population in the city of Hamburg (Germany)
    Aries, Peer
    Iking-Konert, Christof
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (12)
  • [6] Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD
    Benucci, Maurizio
    Damiani, Arianna
    Giannasi, Gianfranco
    Li Gobbi, Francesca
    Quartuccio, Luca
    Grossi, Valentina
    Infantino, Maria
    Manfredi, Mariangela
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (02)
  • [7] A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
    Boulware, David R.
    Pullen, Matthew F.
    Bangdiwala, Ananta S.
    Pastick, Katelyn A.
    Lofgren, Sarah M.
    Okafor, Elizabeth C.
    Skipper, Caleb P.
    Nascene, Alanna A.
    Nicol, Melanie R.
    Abassi, Mahsa
    Engen, Nicole W.
    Cheng, Matthew P.
    LaBar, Derek
    Lother, Sylvain A.
    MacKenzie, Lauren J.
    Drobot, Glen
    Marten, Nicole
    Zarychanski, Ryan
    Kelly, Lauren E.
    Schwartz, Ilan S.
    McDonald, Emily G.
    Rajasingham, Radha
    Lee, Todd C.
    Hullsiek, Kathy H.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (06) : 517 - 525
  • [8] COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine
    Bozzalla Cassione, Emanuele
    Zanframundo, Giovanni
    Biglia, Alessandro
    Codullo, Veronica
    Montecucco, Carlomaurizio
    Cavagna, Lorenzo
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (10) : 1382 - 1382
  • [9] Brikman S, 2020, ISR MED ASSOC J, V22, P439
  • [10] COVID-19: immunopathology and its implications for therapy
    Cao, Xuetao
    [J]. NATURE REVIEWS IMMUNOLOGY, 2020, 20 (05) : 269 - 270